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ABSTRACT: A continuous tandem in-line evaporation−crystallization is presented. The process includes an in-line solvent-
swap step, suitable to be coupled to a capillary based cooler. As a proof of concept, this setup is tested in a direct in-line
acetonitrile mediated crystallization of Vitamin D3. This configuration is suitable to be coupled to a new end-to-end continuous
microflow synthesis of Vitamin D3. By this procedure, vitamin particles can be crystallized in continuous flow and isolated using
an in-line continuous filtration step. In one run in just 1 min of cooling time, ∼50% (w/w) crystals of Vitamin D3 are directly
obtained. Furthermore, the polymorphic form as well as crystals shape and size properties are described in this paper.
1. INTRODUCTION
Crystallization is one of the most important and most
commonly used pathways to separate and purify solid materials
in chemistry, and especially in the pharmaceutical industry.1,2
Particle properties such as size, shape, polymorphism, and
particle size distribution (PSD) play a pivotal role, since they
not only define the crystallization process itself, but also
strongly impact the subsequent downstream processes in the
context of formulation3,4 (e.g., filtration, drying, and milling5).
In addition, the crystallization process can determine eminent
properties of a pharmaceutical drug formulation such as its
bioavailability and stability.6
In May 2015, the Food and Drug Administration (FDA)
opened a new era in chemical manufacturing and called on
pharma manufacturers and Contract Manufacturing Organ-
izations (CMOs) to begin to switch from batch to continuous
production which shall be completed in the year 2025.7 Beyond
this legislative regulatory push, the ACS Green Chemistry
Pharmaceutical Roundtable, and thus the pharmaceutical
industry, have endorsed the same view and declared (small-
scale) continuous manufacturing as top-1 priority.8 Following
this approach, integrated continuous purification and isolation
procedures are needed to achieve a full compact end-to-end
processing. Process simplification is a demand in integrated
flow chemistry,9 which needs accurate process control.10,11
In this paper, a continuous flow crystallization of Vitamin D3
(VD3) is proposed using a new tandem evaporation−
crystallization setup, as an example of process simplification
as well as proof of the advantages of crystallization in-flow. In
the batch process, VD3 is extracted after synthesis (photo-
chemical reaction) first by removal of unreacted 7-dehydrocho-
lesterol (7DHC).12,13 The obtained resin can be used without
further purification in animal feed. Nevertheless, for food and
pharmaceutical use, the resin has to follow additional
purification steps to obtain the crystalline form. For this
purpose, an esterification of the remaining VD3 provides an
alcohol functionality (first step) using organic acids such as
propionic, valeric, or butyric acids. Such esters are more readily
isolated and crystallized (second step). In the next step, a
saponification at max. 80 °C of the purified esters follows,
which is performed under alkaline conditions using e.g. a
solution of potassium hydroxide in methanol (third step). The
isolation of the saponification mixture (fourth step) is carried
out by either using VD3 seeds or adding water before extracting
with ether. The extracted mixture is then washed sequentially
(fifth step) with an aqueous sulfuric or hydrochloric acid, water,
a solution of sodium bicarbonate, and ending with water again.
After this operation, VD3 is obtained as a resin which still
requires further crystallization (sixth step) using an acetone−
water solution in a process which can take the order of days.14
Thus, the isolation of VD3 requires six very long steps in a
cascade process.
In a previous study about VD3 crystallization, we described
in batch the need for a solvent-swap operation, from the
reaction solvent to acetonitrile as the most suited solvent, as a
pathway to obtain pure VD3 crystals.15 The high solubility of
VD3 in the reaction solvent, in this case tert-butyl methyl ether
(t-BME),16 avoids crystallization even at low temperatures.
Transferring the solvent-swap concept to the continuous
process involves a reaction solvent evaporation combined
with a replacement by acetonitrile (solvent B) for the next
crystallization step. The constraint of using a solvent swap via
solvent evaporation, with the subsequent low pressure, makes
the application of segmented flow very difficult. Segmented
flow17 with two immiscible fluids is in addition to the
application of ultrasound,18,19 a rather common way to avoid
undesired blockage20 in continuous applications, since the
particles have only little chance for channel wall deposition.21,22
Other alternatives for small-scale continuous crystallization are
mixed-suspension-mixed-product-removal crystallizers
(MSMPR) as well as capillaries and tubes in the milli- and
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meso-flow23,24 regime. Prominent examples of this approach
are Oslo type crystallizers,25 draft tube baffle crystallizers,26 and
forced/induced circulation crystallizers.27 Yet, also these
approaches are not practicable with a low-pressure solvent-
swap.
In the context of continuous evaporation, only a few
microfluidic concepts have been developed, such as mem-
brane-based separation methods, e.g. pervaporation,28,29 and
thin-film evaporation.30,31 While these approaches are very
sophisticated and are based on microfluidic mechanisms (thin-
layer evaporation, periodic and chaotic evaporation, and
nucleate boiling32), in this study a straightforward process in
the milli-flow range using droplet evaporation is presented. The
latter plays a vital role in various fields of natural science33 and
engineering including cloud physics,34,35 burning liquid-fuels,
air/fuel-premixing, (biological) crystal growth, and paint-
ing.36−38 It allows high heat transfer rates and is therefore
used in spray-cooling, in the electronics industry for cooling of
integrated circuits, and in inkjet printing as the most common
applications.
Thus, a process for tandem evaporation−crystallization
including an in-line solvent swap is herewith described and
proved for the crystallization of Vitamin D3. The evaporation
and heat exchange are characterized by basic equations. Special
emphasis is given on determining the crystal yield and quality,
the latter compared to batch results.
2. EXPERIMENTAL SECTION
2.1. Process Description. Single-Cycle Operation. The
continuous-flow setup used for the solvent-swap and
subsequent crystallization is schematically shown in Figure 1.
A solution of 0.22 M Vitamin D3 (Alfa Aesar, 99% Lot:
10186907) in tert-butyl methyl ether (t-BME; Alfa Aesar, 99%)
is pumped through an IDEX PEEK tube Ora 1/16” ID (0.55
mm) to a T-mixer and mixed with acetonitrile (ACN; Merck
>99.9%). t-BME is the photoreaction solvent currently in use
(solvent A). The VD3 concentration is set according to the
maximum solubility of 7DHC in t-BME used in the
photoreaction (0.22 mol/L).16 Using pure VD3 assumes that
unreacted 7DHC has been removed completely after the
photoreaction to Vitamin D3 and the content of other
byproducts is negligible.
The VD3 solution with the corresponding t-BME−ACN
ratio (A/B) crosses a flow valve (needle valve) to go to the
solvent-swap step. The function of this flow valve is to
counterbalance the vacuum forces derived from the solvent
switch step and to ensure the constant flow rate. The solvent-
swap step is shown in more detail in Scheme 1. The device for
the solvent swap is made out of glass, vertically placed, and kept
at 40 °C using an internal thermocouple (Mohr & CO -
Laborhandelsgesellschaft mbH) and an external heating tape
(Thermocoax Isopad GmbH), and maintained under a constant
pressure of 280 mbar, by using a vacuum controller (Büchi
Labortechnik AG). Due to the different boiling points of the
Figure 1. (a) Scheme of the continuous-flow setup used for solvent-swap and crystallization of Vitamin D3. (b) Detail of the process steps in a single
run (1, solvent-swap; 2, cooler and in-line filter; 3, wet crystals on the filter; 4, final dried Vitamin D3 crystals).
Scheme 1. Schematic Drawing of the Solvent-Swap Step
(Unscaled)
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solvents, selective droplet evaporation happens during the
falling down of the drops and on the surface of the receptacle
placed below the capsule, leaving the VD3 in solvent B. t-BME
is then condensed in a separate flask. Such evaporation is
enhanced by the circular shaped vapor envelope formed around
the drop during the fall, which increases the exchange surface
strengthening both heat and mass transfer.39 In short, fast
evaporation in the swap capsule happens because of the
synergistic interaction of (i) temperature, (ii) pressure, and (iii)
in-fly exchange area enhancement. As a result of super-
saturation, the solution becomes turbid in this step. The
efficiency of the evaporation was checked evaluating the
content of the condensed fraction using Shimadzu apparatus
Model GC-2010 Plus (SGE-BPX5 6, 0.25 mm ID, 1.0 μm
coated column), which indicated that in this operation a 10%
(w/w) loss of acetonitrile is assumed to achieve less than 10%
of t-BME after evaporation.
The supersaturated mixture (see Figure 1) is pumped further
on using two microperistaltic pumps (mp6 micropump, Bartels
Mikrotechnik GmbH) in order to counterbalance the vacuum
forces on the liquid. The solution is transported in this manner
in a perfluoroalkoxyalkane (PFA) 1/8” OD capillary tube (1.55
mm ID DuPont High purity) which acts as precooling zone at
room temperature. After this step, the capillary containing the
supersaturated VD3 solution is submerged in an ethylene glycol
(Unil Opal) cooling bath (Endocal RTE-110) with a
temperature of 7 °C. Cooling of the supersaturated VD3
solution stimulates crystal formation and growth. The crystals
are separated from the solution afterward via a 10 μm pore
stainless steel in-line filter (IDEX A-330). The final mixture
after the VD3 filtration (see Figure 1) contains also a certain
amount of VD3 according to its solubility in ACN at the
temperature set in the cooler.
Multicycle Operation. To mimic a recycling procedure, the
final ACN mixture (permeate from the previous cycle) is
subsequently used as feed for the next cycle. The solution is
mixed with a new 0.22 M Vitamin D3-t-BME solution. As a
consequence, due to the extra vitamin amount contained in the
recycled ACN mixture, the concentration of the solution
mixtures in the subsequent cycles are higher than the
concentration of the solution in the first cycle. This fact
enhances even more supersaturation in the following cycles. In
order to know exactly the vitamin concentration in each cycle,
the concentration of VD3 in the recycled ACN solution is
previously obtained using HPLC measurements (Shimadzu
UFLC-XR; GraceSmart RP 18 5μ, 150 mm × 4.6 mm; 100%
acetonitrile). After each cycle a mass balance of the Vitamin D3
in each fraction is carried out. The masses of the solid parts
(filtered, permeated, and residues in the cooling coil) are
determined after drying the samples overnight under vacuo in a
desiccator, and the samples for further experiments are stored
in the dark at −20 °C under inert gas (nitrogen).
2.2. In-Line Solvent-Swap Operation. The solvent-swap
operation is based on the selective in-line evaporation of t-BME
in three substeps as shown in Scheme 2: (a) in-flight
evaporation, (b) droplet crash, and (c) liquid−gas evaporation
on the surface liquid on the receptacle placed below. The main
aim of this process is to enhance the evaporation surface as
much as possible in order to intensify the mass transfer, and
subsequently the evaporation. During the formation and the fly
of the droplets, a thin layer of saturated vapor is formed around
the droplet, generating an energy transfer during the
evaporation process. Hence, the evaporation of the components
creates concentration gradients in the liquid phase. Since the
cavity is thermally controlled at 40 °C, the process is
considered as isothermal, and consequently mainly mediated
by the mass transfer. The latter is enhanced by the suction
effect of the pump, which keeps the pressure at 280 mbar,
generating and keeping constant the driving force for the
droplet vapor transfer. During the drop formation, evaporation
of t-BME is possible, but also a mass input because of the flow.
For this reason, the content of the solvents is considered almost
stable before the drop falling.
The evaporation of in-fly droplets has been previously
investigated.40,41 Tripathi39 modeled the evaporation of a falling
drop and how the shape of the drop as well as the
microdroplets, generated behind the droplet by the spray effect
of the fall, are changing over time (Scheme 2a). As a
consequence, the volume is redistributed and the shape of
the drop tends to elongate generating a shaped envelope all
around the droplet of a liquid−vapor interface, which is
increased in time. Also, the evaporated mass in the envelope
enhances the mass transfer within the droplet which changes
the density of the droplet. During the flight, the weak interface
generated at the upper part, i.e., microdroplets, increases the
evaporation surface and subsequently the evaporation rate.
Scheme 2. Steps of the In-Line Solvent-Swap (Unscaled): (a) in-flight evaporation, (b) droplet crash, and (c) liquid−gas
evaporation on the surface liquid
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Hence, despite being the shortest step, the evaporation rate
here is the maximum. The 2.6 times difference of the vapor
pressures of the involved solvents at 40 °C, 587.3 and 222.2
mbar for t-BME42 and ACN43 (at atmospheric pressure)
respectively, also contributes to the selectivity of the
evaporation solvent. In the working conditions (40 °C and
280 mbar), the difference between the partial pressures is even
ten times: 255 and 25 mbar for t-BME (solvent A) and ACN
(solvent B) respectively (calculated with Aspen plus v.9, Aspen
Technology Inc.). Therefore, solvent A evaporates 10 times
faster than solvent B. In addition, the partial pressures are 2.5
and 9 times (solvents A/B) below the corresponding vapor
pressures, respectively.
Immediately after the fly, the droplet crashes to the liquid
surface generating again secondary droplets, which enhances
the mass transfer as well (Scheme 2b) because the surface is
also increased. After the crash, the droplet is diluted in the
ACN-VD3 solution. Here the concentration is diffused and the
remaining t-BME (solvent A) is mixed in the first upper layers
of the liquid, and therefore evaporated due to the pressure/
temperature conditions. In order to obtain a rough
approximation for the difference between the in-fly operation
rate (Scheme 2a) and the surface operation rate (Scheme 2c),
the following theoretical approach is proposed. As a
simplification, the mass transfer within the droplet is neglected
and the density of the droplet is considered as constant.
Subsequently, assuming a spherical droplet, its volume (V) and
consequently its diameter (db) are related to the number of
moles of its constituents (nA, nB, nC) according to the following
expression, where MW refers to the molecular weight and ρ to
the density, with A, B as the solvents involved (t-BME and
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Rearranging eq 1 results:
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During the decay of the droplet, its diameter is reduced due
to partial evaporation of its constituents. Assuming that the
density of the droplet does not change significantly during this









































At this point, some simplifications can be assumed in eq 3 for
the purposes of this study. First, due to one of the components
of the mixture (i.e., C) being unable to evaporate under the




C ), eq 3 can be
further reduced accordingly. Second, if the mole balance of A
and B in the spherical particle assuming isothermal conditions
is derived, the accumulation of each component in the droplet
equals the mass transfer rate of such a component from the
droplet to the gas phase (concentration C) through the gas−
liquid interfacial area (AGL). Additionally, the interfacial mass
transfer rate is characterized by the overall mass transfer




i·s). In eq 4, the
concentrations of A and B in the vapor are assumed constant
under stable conditions.
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Assuming ideal gas law, and including the relation between
interfacial area and bubble diameter (AGL = π·db
2), the
expressions 4 can be as described respectively in eq 5, where
Psat is the vapor pressure.
= − ·π· ·
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Then, the interfacial mass transfer rate is characterized by the
overall mass transfer coefficient (kGL) expressed in units of
[m3G/(m
2
i · s)]. The mass transfer coefficient kGL is determined




























Therefore, the depletion of solvents A and B in the droplet
can be correlated with the size of the droplet and the velocity of
the droplet, which for a free falling droplet in vacuum is v = g·t,
giving eq 8. The mathematical solution of eq 8 was obtained









































Concerning the evaporation on the surface once the droplet
is submerged in the liquid, eq 9 gives the expression of the rate
of ether evaporation (N) (mol·m−2·s−1) dissolved in the very
first layers of the mainly solvent B solution placed in the
receptacle. In eq 9, c refers to concentration, P and T are the
pressure and temperature in the evaporation chamber


































Since the p,T conditions in the evaporation chamber are
constant and considering that every evaporated molecule is
transferred to the cooler of the condenser, the evaporation ratio
could be considered almost constant.
Both substeps of the solvent swap are plotted in Figure 2,
where a comparable volume reduction of the droplets is shown.
Hence, it can be concluded that the evaporation rate during the
in-fly step (0.17 s) is 100 times faster than the comparable
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evaporation on the surface, where the solution becomes
basically a VD3 solution in acetonitrile. Additionally, a
simulation of the solvents evaporation on the surface was
performed using Aspen plus v.9 (Aspen Technology Inc.),
adjusting all thermodynamic properties according to Mato et
al.45 For an initial ratio of 1:3 v/v % A/B, 96:4 w/w % A/B in
the gas phase and 4:96 w/w % A/B in the liquid phase were
obtained.
These theoretical approaches were checked experimentally
using the evaporation−crystallization setup. Due to the lower
solubility of VD3 in the solvent B, supersaturation is reached in
the receptacle and the solution becomes opaque after 5 min.
The whole evaporation process reaches 20% of the initial
droplet volume. This could mean that one-third of evaporation
is taken in-fly in just 0.17 s. The flow rates of the pumps were
adjusted according to the cooling flow-rate needed in the cooler
to set the 1 min cooling time. In addition, the composition of
the final solution after the evaporation step was determined
experimentally using gas chromatography (Shimadzu GC-2010
Plus). The results show that using 1:3 A/B (v/v), >90 wt % of
A can be removed at 40 °C and 280 mbar including a 10 wt %
loss of B. The slight difference between the simulation and the
experimental results can be explained by the interaction of the
solvents with the dissolved VD3.
2.3. Process Temperature Profile. In our crystallization
process, the temperature plays a critical role, as the solubility of
Vitamin D3 is strongly temperature dependent.
15,46 Thus, an
accurate prediction of the temperature profile during the
process is essential. Herewith, the temperature is analyzed from
the solvent-swap cavity, where supersaturation takes place, and
followed along the cooler. Out of the swap chamber, where the
temperature is monitored and kept constant at 40 °C, two
additional steps are considered: (i) the precooling section
which includes the peristaltic pumps between the solvent swap
and the cooler, and (ii) the cooler itself. In the precooling
section, heat transfer by conduction (φk) and by convection
(φh) are considered as shown in eq 10. In these equations h
(599 W/m2·K)) and k (0.213 W/m·K) are the convection and
conduction coefficients respectively, cp is the ACN heat capacity
(2.2 J/g·K), and L is the wall thickness of the capillary (0.81
mm). For these calculations, laminar flow in the circular tube
(Nusselt number = 4.36) was considered, assuming only
acetonitrile as solvent B. The acetonitrile parameters were
considered as an average, since they do not change so much in
the range of temperatures taken into account. In addition, ΔT1
in eq 10 refers to the difference between the environment
temperature and the external wall of the coil (convection).
Analogously, ΔT2 is the difference between the internal and the
external side of the coil (conduction) and ΔT3 is the difference
between the internal side of the coil and the solution inside it.
As a simplification, the single-operation calculation for each of
the two cooling steps was performed without considering heat
conduction with the connected parts. In practice, this effect was
reduced as much as possible by insulation.
= = · ·Δ = · ·Δ = ̇ · ·ΔQ h A T k L T m C TØ Ø ;h k p1 2 3 (10)
Considering the first two sides of eq 10, the temperature of
the wall can be calculated. In the precooling section the wall
temperature is 312.5 K and in the cooler it is 293 K. This
suggests that the internal wall is almost at the same temperature
of the internal mixture. Then, considering the last two sides of
Figure 2. Calculated equivalent drop volume evaporation.
Figure 3. Calculated process temperature profile in the crystallization unit using a flow rate of 15 mL/h.
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eq 10, the dropping temperature can be calculated. Figure 3
plots the temperature profile (Y-axis) from the solvent-swap
cavity, crossing the peristaltic pumps in the precooling section
as well as the cooling operation, along the length of the
capillary (X-axis). Discrete values refer to the calculation of
cooling down. The constant temperature (processing) period is
assigned to be the desired set value. The time periods for
cooling down are revealed by guidelines for the eye. The
precooling section corresponds to the length of the coil at room
temperature (20 °C) between the swap cavity and the cooler,
and the cooling section, to the length submerged in the cooler.
As shown in Figure 3, due to the high heat transfer of the
capillary tubes and the low volume inside the capillary, the
target temperature is set in the very first sections of the tubing
for each step: after the 24 mm tube length in the precooling
section and after the 16 mm tube length in the cooling section.
Consequently, despite having a short cooling time, the
temperature can be considered to be constant for the whole
cooling process.
2.4. Crystals Analysis. Particle Size, Shape, Crystallinity.
The obtained Vitamin D3 crystals were analyzed using a Leica
DM4000 M microscope (50× magnification) with an
integrated digital camera. X-ray diffraction (XRD) crystals
analysis was carried out with a Rigaku Geigerflex Bragg−
Brentano Powder Diffractometer with nickel filtered Cu Kα
radiation (λ = 0.1542 nm), performed with 0.02 step in the 2θ
range of 0°−90°, and a dwell time of 2 s operating at 40 kV and
30 mA. Peak fitting was performed after background
subtraction. Subsequent crystal morphology analysis was
characterized using a Scanning Electron Microscope (SEM)
JEOL JSM-7401F. Raman data were obtained using a
PerkinElmer Raman Station 400 F. The exposure time was 1
s, and the number of exposures was 10. Sampling Super Macro
Point (7 points), the wavelength range investigated was 200−
3278 cm−1 with an interval of 2 cm−1.
Particle Size Distribution. The particle size distribution of
the obtained Vitamin D3 crystals was measured as a suspension
in water using a drop of Tween20 as tenside with a HELOS/
KR Laser diffraction sensor equipped with a CUVETTE wet
dispersion system by Sympatec GmbH (cuvette size: 50 mL,
stirring speed: 1000 rpm, optical concentration: 1%−20%,
measuring range: combined R2+R5 (0.45−875 μm), evaluation
mode: Fraunhofer approximation, software: WINDOX 5.6.0.0).
Particle Purity. In order to evaluate the purity of the
obtained crystals and thus ensure that no decomposition of the
VD3 occurred, 1.25 mg of commercial and obtained crystals
were dissolved in 1.5 mL of acetonitrile and injected in the
HPLC instrument (Shimadzu UFLC-XR) with a GraceSmart
RP 18 5μ column (150 mm × 4.6 mm), using 100% acetonitrile
(99% Merck) as the mobile phase and a UV−visible Shimadzu
diode array detector (RID-10A) at 190 nm.
3. RESULTS AND DISCUSSION
3.1. Single-Cycle Experiments. 3.1.1. Residence Time vs
Temperature Influence. Choice of Flow Rate. Since the flow
rate of the photochemical reaction was fixed with 15 mL/h, the
same flow rate was applied for the crystallization process in
order to allow the integrated flow system finally work with one
pump. A 1/8” ID (1.55 mm) PFA tubing of 130 mm length was
used in the cooler. The reason for the dimensional choice of the
capillary diameter was to allow high heat transfer, while having
it set sufficiently large to avoid particle-related problems. The
dimensional choice of the capillary length is based on the
photochemical reaction and crystallization times, being some-
what shorter than 1 min for the first and exactly 1 min for the
latter, respectively.
Motivation and Hydrodynamic Residence Time. We aimed
first to determine the right temperature and residence time
(capillary length) as well as to check if sufficiently small crystals
can be produced and if the crystals are small enough to not
disturb the flow or even block the channel. The requirement
was that the crystal size is at least 100 times smaller than the
channel diameter. As residence time, we calculated the
hydrodynamic residence time for an empty capillary using the
flow rate of the solvent. This simplification ignores the presence
of crystals in the real flow and a possible shrinkage of the
capillary diameter due to crystal deposition on the walls. Both
effects would decrease the real residence time of the solvent.
Yet ignoring both effects seems to be justified, since the particle
loading is low (4% given as mg crystals/mg solvent in 1:3 t-
BME/ACN ratio) and the amount of deposited crystals in the
capillary diameter is estimated to be <0.4 wt % (as known from
some tests on cut samples). The residence time calculated thus
is assumed to be characteristic for the real solvent flow and the
cooling process enabled through the latter. The residence time,
however, is not characteristic for the formed and flowing
crystals which may have a different residence time than the
flow, probably slower.
Choice of Temperature. The crystallization was first studied
at temperatures of 0, 5, 10, 15, and 20 °C using a residence
time of 1 min (0.13 m capillary length). With these
experiments, a very narrow temperature range of operation
was determined: above 10 °C, no crystals were retained in the
filter; below 5 °C, the capillary was clogged. Thus, 7 °C was
finally used to carry out the crystallization. The mean diameter
of the crystals produced in this way was <10 μm. Thus, the
milli-capillary size was at least 155 larger which should ensure
an undisturbed flow, if agglomeration can be prevented.
Choice of Residence Time. It was therefore aimed to use
longer residence times which might allow a larger temperature
range. The residence time was adjusted by varying the lengths
of the capillary. The latter were set to 0.13, 0.25, and 1.00 m,
corresponding to theoretical residence times of 1, 2, and 7.54
min, respectively (flow rate was 15 mL/min). Yet, the use of
longer residence times than 1 min was not helpful, as plugging
occurred in the longer flow passages. This happened typically in
the first third of the longer capillary.
Experimental Reference Conditions. Overall, with a PFA
tubing of 130 mm and 1.55 mm ID and a flow rate of 15 mL/h,
a residence time of 1 min was used, and a temperature of 7 °C
was chosen in all further experiments. With these parameters, a
very fast crystallization of Vitamin D3 was achieved.
3.1.2. Effect of Solvents Ratio. We assumed that the solvent
A−solvent B ratio is a pivotal parameter for the crystal size and
crystallization speed as well as for the agglomeration. Different
ratios were studied using a temperature of 7 °C and the above-
defined standard conditions (see Table 1). The amount of VD3
in different fractions was determined: f iltered as desired and
retained as value product, permeated through the filter and
dissolved to be recycled and refed in the flow, and the amount
deposited on the capillary walls which is lost for further
processing (see also Experimental Section, 2.1). All three
fractions are referred to the total VD3 load introduced. The
results in Table 1 show a consistent mass balance, as all three
fractions (recuperation) are above 90%.
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As shown in Table 1, two parameters were taken for further
optimization: The crystal yield is identical to the filtered
amount. It is the crystal mass filtered divided by the total initial
VD3 mass (eq 11). The process efficiency is the crystal mass
filtered divided by the total initial VD3 mass minus the
dissolved amount at 7 °C (eq 11). It thus defines a crystal yield
which is corrected with the solubility of VD3 in the solvent, i.e.
the amount of crystals filtered off as referred to all molecules
which principally (thermodynamically) could crystallize.
Following the terminology of “yield”, the process efficiency is
a kind of “selectivity”. The calculated efficiency is a minimum
possible value, because it does not include particles below 10










initial mg VD3 mg VD3 soluble (11)
For the single cycle experiments, the highest crystal yield and
process efficiency were 53% and 74% for a starting solvent
mixture of 1:3 t-BME/ACN, respectively. This was considered
as a proof of principle, since achieving 100% crystallization yield
is not possible, even when using another solvent B, as there is
always a fraction of VD3 dissolved in such solvent B.
The solubility of VD3 in ACN was determined to be 8 mg/
mL at 7 °C.15 This is about 10% of the possible crystal load (84
mg/mL). This fraction is for processing the inaccessible and
not a big issue, as the permeate can be recycled. This solvent B
solubility will, however, become especially relevant when low
amounts of the vitamin are used, as then its share and the
amount of recycling steps greatly increase. Thus, the
continuous crystallization process developed is usable for high
VD3 concentrations which are typical for chemically intensified
flow chemistry, however, not for diluted flows.
Interestingly, the solvent B (ACN) addition to the solvent A
(t-BME) results in an antagonistic effect, as shown in Table 1.
An increasing amount of the solvent B, on one hand, promotes
crystallization, but on the other hand also dissolves increasing
amounts of VD3. Thus, the yield of VD3 exhibits a maximum
with a solvent A−solvent B ratio of 1:3. The permeated fraction
increases because of the higher amount of VD3 dissolved in
ACN. Furthermore, the amount of crystals deposited in the
capillary decreases when a higher proportion of solvent B is
added. The reason therefore is either a lower concentration
leads to less clogging or crystals themselves become smaller and
thus are less prone to crystal agglomeration. At high solvent B
share, also the increased solubility simply cleans the crystals
attached to the capillary.
Hence, in the way supersaturation is increased (and the
solvent B amount decreases), more crystals are retained in the
system, which reduces the filtration efficiency and, conse-
quently, the final yield. Nevertheless, when the solvent B ratio is
increased too much, the solubility losses become relevant and
the amount of crystals in the filter decrease.
3.2. Multicycle Experiments. While a high crystal yield
could be reached in one run, the given analysis has shown that
recycling is needed, even under better and best performance.
Therefore, this is investigated here and up to three cycles were
considered at the standard processing conditions. In addition to
the three shares of VD3, its concentration in the permeate is
given in Table 2. As shown, the final concentration of the
permeated fraction after each cycle remains almost constant,
but above the amount corresponding to the solubility of the
Vitamin in ACN at 7 °C. This is attributed to particles with a
diameter below 10 μm which are smaller than the pores of the
filter and just pass through. As the permeated fraction was not
thermostated at 7 °C, those crystals redissolved at the higher
temperature.
For the 1:3 (v/v) ratio of the starting solvent mixture, the
filtered share (crystal yield) decreases, while it increases for the
1:4 ratio. The deposited and permeated share behave
conversely in the capillary. The shares of the second and
third circle match better than the first one, which could be
indicative of increased process stability. The recuperation of
this mass balance has an average around 90%.
The 1:4 case thus gives better performance (more crystal
yield) because of two effects: the higher starting concentration
due to mixing of additional VD3 to the inflow through
recycling. This changed concentration necessitates a higher
acetonitrile share in the solvent mixture which provides a higher
supersaturation, i.e., the driving force for nucleation. Addition-
ally, the efficiency is almost stable using 1:4, which could be set
at ∼55% per run.
Table 1. Mass Balance, Crystal Yield, and Process Efficiency
at Different Solvent A−Solvent B Ratios







ACN Permeated Filtered Deposited
1:1.5 13 23 59 23 33
1:2 22 36 42 36 60
1:3 34 53 12 53 74
1:4 54 32 7 32 35
Table 2. Multicycle Experiments at 7 °C and 1 min Cooling Time
Mass Balance (%)
t-BME/ACN ratio Cycle VD3
a in ACN (mg/mL) Permeated Filtered Deposited Yield (%) Efficiency (%)
1:3 1 − 34 49 15 49 69
2 10 24 41 18 41 52
3 9.5 24 42 20 42 53
1:4 1 − 56 29 7 29 55
2 10.5 38 38 12 38 55
3 9.5 42 37 14 37 53
aRemaining VD3 added from the permeated ACN of the previous cycle.
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Furthermore, the initial concentrations for each cycle were
determined according to the experimental data provided in
Table 2, giving the results shown in Table 3. For these values,
the amounts of VD3 dissolved in the recycled solvent B
solution and therefore mixed with a fresh solution of VD3 in
solvent A were considered. In light of the results shown in
Table 3, and taking into account the highest yields shown in
Table 2, we could conclude that the optimal concentration of
VD3 for this operation is in the range of 30−35 mg/mL. This
range is also quite narrow, since lower concentrations (e.g., 21
mg/mL) would lead to lower yields, because more VD3 is
dissolved. Unfortunately, higher concentrations also give more
VD3 deposited on the capillary, which also leads to higher
losses.
3.3. Crystals Characterization. 3.3.1. Purity of the
Crystals. Cholecalciferol (VD3) can be unstable and degrade
in the presence of oxygen and humidity,47 but also because of
operation conditions. This lack of stability may be detected
using HPLC analysis. To study the final purity of the vitamin
particles after the process, the crystals obtained were compared
with a commercial VD3 using HPLC and the protocol
described in paragraph 2.4. As a result, a high level of purity
fully comparable with the commercial Vitamin D3 was achieved
as shown in Figure 4. In addition, some experiments were
carried out in anhydrous conditions using dried and
deoxygenated solvents, in order to test the VD3 stability. For
this purpose, ACN was refluxed for 2 h with CaCl2 prior to
distillation. The same procedure was used for t-BME using
MgSO4 as a drying agent. In both solvents, dry nitrogen was
passed through for a few minutes for deoxygenation. The
experiments in anhydrous and deoxygenated conditions did not
show any degradation of VD3.
3.3.2. Crystal Polymorphism. The polymorphic form of the
obtained crystals (7 °C, 1 min cooling time) was analyzed using
both XRD and Raman spectroscopy using the devices described
in 2.4 and were referred to the forms A and B described by
Wang et al.48 We previously reported the possibility to obtain
separately form A and form B in batch conditions using solvent
B (ACN) and temperature <15 °C.15 Commercial VD3 was
analyzed and correlated with form A. Form B was also
correlated in batch with fast processing and low crystallization
temperatures. Using the continuous process herewith reported
(Figures 5 and 6), the obtained VD3 crystals analysis gives
mainly Form B, however also with a small fraction of Form A.
In the XRD plot (Figure 5) form B signals can be found at
3.54°, 6.16°, and 9.44°, while form A ones are found in 4.74°,
5.06°, and 6.62°. In addition, the Raman spectrum of the
obtained crystals (Figure 6) shows both, form B and form A
signals between 2700 and 3000 cm−1. According to our
experiments in batch, form A is formed when the starting
temperature is higher than 20 °C. Hence, the presence of form
A in the crystals obtained in the continuous process could be
explained because of the conditions in the solvent-swap step,
which operates at 40 °C in order to enhance the evaporation.
3.3.3. Particle Shape and Particle Size Distribution. The
crystal habit depends not only on the internal structure of the
crystals but also on the growth conditions. For continuous
processing the crystal habit takes an important role, because it
can easily affect the rheological properties as well as the
filtration efficiency of the process. Accordingly, the VD3
crystals obtained with the continuous setup (7 °C, 1 min
cooling time) were analyzed using light microscopy and
scanning electron microscopy (SEM) described in 2.4. Figure
7 shows a comparison between the particle sizes obtained using
the continuous process (upper) and the commercial particles
(lower). As it can be seen in the graph, the new particles here
obtained are prismatic and smaller than the commercial ones
(Alfa Aesar, 99% Lot: 10186907). The latter is quantified in
Figure 8. The mean size of the continuous obtained particles is
around 10 times smaller (∼16 μm) than the commercial VD3
(∼114 μm). It can be assumed that the smaller size is due to
the fast crystallization conditions, which is correlated with a
short crystals growth time. Such small crystals would be
preferred in continuous-flow crystallization in order to
guarantee the flowability and avoiding undesired clogging. In
addition, the wide distribution of the particles obtained with
this continuous process can be explained because of some
damages during the recovery operation on the filter.
■ CONCLUSIONS AND OUTLOOK
A continuous tandem in-line evaporation−crystallization was
designed and tested with the crystallization of Vitamin D3. By
using this procedure as well as the knowledge of the research
group in direct Vitamin D3 crystallization in batch using
ACN,15 it is possible to avoid the amorphous state of the
vitamin (yellow resin). The proposed method achieves the
objective of an integrated, simple and intensified process, using
shorter times as well as a much lower amount of chemicals. The
necessary solvent change was successfully achieved using a
solvent-swap cavity especially designed to converge temper-
ature, pressure, and spray effect due to drop falling.
By applying this configuration in the case of Vitamin D3
crystallization, the solvent A/B (t-BME/ACN) ratio of 1:3 (v/
Table 3. Concentrations (mg/mL) in Multicycle






Figure 4. Fragment of overlapped HPLC chromatogram (190 nm) of
Vitamin D3, as obtained in this paper (straight line) and from
commercial sample (dotted).
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v) led to the highest crystal yield and crystal efficiency, the first
referring to the total Vitamin D3 content and the second to the
Vitamin D3 content amenable for crystallization (as part of it
dissolves still in the solvent B), respectively. For the higher ratio
of 1:4 enhanced dissolution by the solvent B is given. A
crystallization yield of 53% is obtained in one run operating at 7
°C during just 1 min of cooling time, yet still below what
theoretically would have been possible, but with very short
process times. Therefore, multicycle experiments simulated a
recycling process, by re-entering the outflowing permeate
solution in another (separate) experiment. These experiments
showed that a 1:4 (v/v) ratio is more advantageous because of
the higher flowability of the crystals in the capillary. The second
and third cycle match in their performances, giving an
indication that stable performance might be given from here
onward.
The continuous process showed polymorphism yielding a
mixture of form A and B, with B being the most prevalent
Figure 5. XRD spectra of the Vitamin D3 crystals obtained in a continuous flow operating at 7 °C during 1 min cooling time.
Figure 6. Raman spectrum of the Vitamin D3 crystals obtained in a continuous flow operating at 7 °C during 1 min cooling time.
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species. The continuously obtained crystals are prismatic and
almost 10 times smaller than commercial crystals, which is
beneficial for proper, uninterrupted capillary continuous
operation.
In light of all the results and process design, an outlook for
the crystallization process directly coupled to the syntheses part
is shown in Figure 9. After the synthesis module ACN will be
added and the solvent-swap discussed in this contribution
allows t-BME recycling. After the cooler, a flow swap sets an
alternative path to the filtration step, allowing an automatic
purge system in the nonflowing line. The mixture of Vitamin
D3 and ACN obtained after the filter can be recycled while
maintaining the solution at increased temperature in order to
avoid undesired precipitations. Thus, the process will allow
pure Vitamin D3 crystals to be obtained while recycling all
solvents. Future approaches will concentrate on the applic-
ability of the proposed procedure for Vitamin D3 and will
further investigate the versatility of the novel process for the
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Figure 7. Microscope and SEM pictures of continuous Vitamin D3 crystals (top) obtained operating at 7 °C during 1 min cooling time, compared
with commercial Vitamin D3 (bottom).
Figure 8. Particle size distribution of Vitamin D3 crystals obtained
operating at 7 °C during 1 min cooling time, compared with
commercial Vitamin D3 (Alfa Aesar, 99% Lot: 10186907).
Figure 9. Outlook of the full crystallization setup for medium scale
production.
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